Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Krystal Biotech (KRYS) Shares Outstanding (Weighted Average) (2021 - 2025)

Historic Shares Outstanding (Weighted Average) for Krystal Biotech (KRYS) over the last 5 years, with Q3 2025 value amounting to $29.0 million.

  • Krystal Biotech's Shares Outstanding (Weighted Average) rose 82.53% to $29.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $29.0 million, marking a year-over-year increase of 82.53%. This contributed to the annual value of $28.6 million for FY2024, which is 529.57% up from last year.
  • As of Q3 2025, Krystal Biotech's Shares Outstanding (Weighted Average) stood at $29.0 million, which was up 82.53% from $28.9 million recorded in Q2 2025.
  • Over the past 5 years, Krystal Biotech's Shares Outstanding (Weighted Average) peaked at $29.0 million during Q3 2025, and registered a low of $21.3 million during Q1 2021.
  • For the 5-year period, Krystal Biotech's Shares Outstanding (Weighted Average) averaged around $26.2 million, with its median value being $26.7 million (2023).
  • Its Shares Outstanding (Weighted Average) has fluctuated over the past 5 years, first skyrocketed by 1816.62% in 2022, then surged by 82.53% in 2025.
  • Krystal Biotech's Shares Outstanding (Weighted Average) (Quarter) stood at $22.2 million in 2021, then rose by 14.85% to $25.5 million in 2022, then increased by 6.52% to $27.2 million in 2023, then grew by 5.3% to $28.6 million in 2024, then rose by 1.26% to $29.0 million in 2025.
  • Its Shares Outstanding (Weighted Average) stands at $29.0 million for Q3 2025, versus $28.9 million for Q2 2025 and $28.8 million for Q1 2025.